SDC1 and Miyoshi myopathy: Finally, the response to 1st line therapy represents one of the most efficient and accurate markers for MM risk-stratification and adjustment of treatment decisions, and the concurrent evaluation of CD138+ miR-25 greatly ameliorated its predictive strength.